Skip to main content

Table 1 Characteristics of studies included in the meta-analysis

From: Prognostic role of myeloid-derived suppressor cells in cancers: a systematic review and meta-analysis

Study

Year

Country

Sample size

Cancer types

Phenotype

Cut-off

Age

Follow-up (month)

NOS scores

Survival analysis

Zhang, Y

2017

China

76

rectal carcinoma

HLA-DRCD33+CD11b+

3.68

NA

NA

5

OS

Yang, G

2017

China

113

bladder cancer

HLA-DRCD33lowCD11b+CD3

21

66.5 (45–84)

43 (4–60)

6

OS

Gao, X.H

2017

China

183

HCC

HLA-DR-/lowCD14

2.31

NA

24 (1.3–28.8)

6

OS, RFS

Wang, D1

2016

China

92

HCC

HLA-DR-/lowCD14

14.6

NA

NA

6

OS

Wang, D2

2016

China

92

HCC

HLA-DR-/lowCD14

14.6

NA

NA

6

OS

Choi, H.S

2016

Korea

28

GC

HLA-DRCD11b+CD14+CD45+

2.2

37–88

29 (10–42)

8

OS, DFS

Zhang, H1

2015

China

32

NK/T lymphoma

HLA-DRCD33+CD11b+

1.1

40.5 (17–70)

52

7

OS, DFS

Zhang, H2

2015

China

32

NK/T lymphoma

HLA-DRCD33+CD11b+CD14+

0.7

NA

NA

7

OS, DFS

Yuan, L1

2015

China

64

rectal carcinoma

LinHLA-DRCD33+CD11b+

3.78

62 (38–76)

72

5

OS

Yuan, L2

2015

China

64

rectal carcinoma

LinHLA-DRCD33+CD11b+

2.11

NA

NA

5

OS

Tian, T

2015

China

42

small-cell lung cancer

HLA-DR-/lowCD14

21.7

62.4

36

6

OS

Jiang, H

2015

Germany

51

advanced melanoma

HLA-DRCD11b+CD14+CD15

2.3

61.26 (33–88)

7

8

OS

Huang, H

2015

China

78

ESCC

HLA-DR-/lowCD14

2.38

62.4 (46–77)

42

7

OS

Chevolet, I

2015

Belgium

69

melanoma

LinHLA-DRCD33+CD11b+

4.13

NA

39

7

OS

Weide, B

2014

Australia

94

advanced melanoma

HLA-DR-/lowCD11b+CD14+

11

NA

15

9

OS

Wang, L

2013

Singapore

40

GC

LinHLA-DRCD33+

4

NA

NA

7

OS

Arihara, F1

2013

Japan

123

HCC

HLA-DR-/lowCD14

22

NA

NA

7

RFS-U

Arihara, F2

2013

Japan

123

HCC

HLA-DR-/lowCD14

22

NA

NA

7

RFS-U, RFS-M

Solito, S1

2011

Italy

25

colorectal cancer

LinHLA-DRCD33+CD11b+

2.54

NA

NA

9

OS

Solito, S2

2011

Italy

26

bresat cancer

LinHLA-DRCD33+CD11b+

3.17

NA

NA

9

OS

Gabitass, R.F

2011

UK

256

pancreatic, esophageal and gastric cancer

Linlow/-HLA-DRCD33+CD11b+

2

NA

NA

7

OS

  1. HCC hepatocelluar carcinoma, GC gastric cancer, ESCC esophageal squamous cell carcinoma
  2. NA not applicable, NOS the Newcastle–Ottawa Quality Assessment Scale
  3. OS overall survival, DFS disease-free survival, RFS recurrence-free survival, U&M univariate & multivariate survival analysis